Table 1.
Demographic and clinical characteristics of recipients with and without new-onset diabetes millitus after liver transplantation (n = 528) n (%)
| Characteristics | Total (n = 528) | NODM group (n = 131) | Non-NODM group (n = 397) | P value |
| Recipient characteristics | ||||
| Age (yr) | 44.93 ± 9.41 | 46.24 ± 9.54 | 44.50 ± 9.34 | 0.068 |
| Gender (male) | 446 (84.5) | 144 (87.0) | 332 (83.6) | 0.352 |
| Child-Pugh (A/B/C) | 136/223/169 | 39/44/48 | 97/179/121 | 0.069 |
| MELD Score | 13 (6-40) | 15 (6-40) | 13 (6-40) | 0.010 |
| BMI ≥ 25 pre-LT | 110 (20.8) | 36 (27.5) | 74 (18.6) | 0.006 |
| Hypertension pre-LT | 12 (2.3) | 7 (5.3) | 5 (1.3) | 0.017 |
| Dyslipidemia pre-LT | 41 (8.2) | 15 (11.5) | 26 (6.5) | 0.069 |
| Indications for LT | ||||
| Hepatitis B virus disease | 420 (79.5) | 102 (77.9) | 318 (80.1) | 0.582 |
| Hepatitis C virus disease | 6 (1.1) | 1 (0.8) | 5 (1.3) | > 0.990 |
| Alcoholic cirrhosis | 16 (3.0) | 7 (5.3) | 9 (2.3) | 0.137 |
| Tumors | 269 (50.9) | 56 (42.7) | 213 (53.7) | 0.030 |
| Mean cTAC (ng/mL) | 5.26 ± 2.91 | 7.66 ± 3.41 | 4.47 ± 2.22 | < 0.001 |
| Rapamycin administration | 129 (24.4) | 30 (22.9) | 99 (24.9) | 0.638 |
| MMF administration | 322 (61.0) | 78 (59.5) | 244 (61.5) | 0.696 |
| Complications post-LT | ||||
| BMI ≥ 25 post-LT | 128 (24.2) | 40 (30.5) | 88 (22.2) | 0.053 |
| Hypertension post-LT | 67 (12.7) | 22 (16.8) | 45 (11.3) | 0.104 |
| Dyslipidaemia post-LT | 175 (33.1) | 63 (48.1) | 112 (28.2) | < 0.001 |
| Cardio-cerebral events post-LT | 18 (3.4) | 10 (7.6) | 8 (2.0) | 0.005 |
| CKD post-LT | 91 (17.2) | 28 (21.4) | 63 (15.9) | 0.148 |
| AR post-LT | 58 (11.0) | 20 (15.3) | 38 (9.6) | 0.071 |
| CR post-LT | 20 (3.8) | 9 (6.9) | 11 (2.8) | 0.062 |
| Infection post-LT | 165 (28.7) | 65 (36.7) | 100 (25.2) | 0.042 |
| Graft failure | 52 (9.8) | 20 (15.3) | 32 ( 8.1) | 0.016 |
| Donor characteristics | ||||
| Age (yr) | 34.01 ± 8.75 | 33.62 ± 8.33 | 34.13 ± 8.89 | 0.559 |
| Gender (male) | 443 (84.5) | 108 (82.4) | 335 (84.4) | 0.600 |
| Donor type (LDLT) | 158 (29.9) | 34 (26.0) | 124 (31.2) | 0.252 |
NODM: New-onset diabetes mellitus; Age: Age at transplantation; MELD: Model for end-stage liver disease; BMI: Body mass index; LT: Liver transplantation; cTAC: Tacrolimus trough concentration; MMF: Mycophenolate mofetil; CKD: Chronic kidney disease; AR: Acute rejection; CR: Chronic rejection; LDLT: Living donor liver transplantation.